Big pharma spends more on share buybacks, but R&D? Not so much

By Gretchen Morgenson (originally published by The New York Times) - Under fire for skyrocketing drug prices, pharmaceutical companies often offer this response: The high costs of their products are justified because the proceeds generate money for crucial research on new cures and treatments…

[Cross-posted from The New York Times publication of July 14, 2017
at https://www.nytimes.com/2017/07/14/business/big-pharma-spends-on-share-buybacks-but-rd-not-so-much.html]

, ,

No comments yet.

Leave a Reply

developed by bodhiWeb